Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $31.85 million versus the consensus estimate of $31.34 million.

2016 Financial Guidance

Vanda expects to achieve the following financial objectives in 2016:

• Net product sales from both HETLIOZ® and Fanapt® of between $143 and $153 million.
• HETLIOZ® net product sales of between $73 and $78 million.
• Fanapt® net product sales of between $70 and $75 million.
• Non-GAAP Operating expenses, excluding cost of goods sold, of between $125 and $135 million. The primary drivers of the expected increase over the prior year are investments in the U.S. Fanapt® and European HETLIOZ® commercial businesses.
• Non-GAAP Operating expenses also excludes intangible asset amortization expense of $10.9 million and stock-based compensation of between $9 and $11 million.
• Year end 2016 Cash is expected to be between $123 million and $143 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.